This is a protocol preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
Protein post-translational modifications (PTMs) represent an untapped source of targets of huge biological interest and therapeutic potential. Their validation can only be indirect, because PTMs cannot be selectively hit by nucleic-acid based interference approaches. Here we describe the protocol for Post-translational Intracellular Silencing Antibody technology (P.I.S.A.), a method for the selection of intrabodies targeting the native acetylated version of proteins and their use for PTM-selective targeting and functional interference in living cells.
Keywords
intrabodies, post-translational modifications, two-hybrid, IACT, PISA, intracellular antibodies
Figure 1
Figure 2
The authors declare no competing financial interests
This is a list of supplementary files associated with this preprint. Click to download.
- supplement0.docx
Table 1 Sequences of validated acetylase domains and linkers Sequences of validated acetylase domains and linkers
- supplement0.docx
Reagents, media, solutions, equipment Reagents, media, solutions, equipment
- supplement0.docx
PISA screening protocol PISA screening protocol
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 17 Jan, 2017
Community comments: 1
Metrics
Comments: 0
HTML Views: ...
Associated Publications
Post-translational selective intracellular silencing of acetylated proteins with de novo selected intrabodies
by Michele Chirichella, Simonetta Lisi, Marco Fantini, +7
Nature Methods (17 January, 2017)
Method Article
Version History
CURRENT STATUS: Posted
Version 1
Posted 17 Jan, 2017
Community comments: 1
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
Protein post-translational modifications (PTMs) represent an untapped source of targets of huge biological interest and therapeutic potential. Their validation can only be indirect, because PTMs cannot be selectively hit by nucleic-acid based interference approaches. Here we describe the protocol for Post-translational Intracellular Silencing Antibody technology (P.I.S.A.), a method for the selection of intrabodies targeting the native acetylated version of proteins and their use for PTM-selective targeting and functional interference in living cells.
Figure 1
Figure 2
Loading...
Associated Publications
Post-translational selective intracellular silencing of acetylated proteins with de novo selected intrabodies
by Michele Chirichella, Simonetta Lisi, Marco Fantini, +7
Nature Methods (17 January, 2017)